EBITDA Margin % is calculated as EBITDA divided by its Revenue. Y-mAbs Therapeutics's EBITDA for the
three
months ended in Dec. 2023 was $-3.04 Mil. Y-mAbs Therapeutics's Revenue for the
three
months ended in Dec. 2023 was $23.36 Mil. Therefore, Y-mAbs Therapeutics's EBITDA margin for the quarter that ended in Dec. 2023 was -13.00%.
Y-mAbs Therapeutics EBITDA Margin % Historical Data
The historical data trend for Y-mAbs Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Y-mAbs Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y-mAbs Therapeutics EBITDA Margin % Distribution
For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Y-mAbs Therapeutics's EBITDA Margin % falls into.
Y-mAbs Therapeutics EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Y-mAbs Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Y-mAbs Therapeutics EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Y-mAbs Therapeutics (Y-mAbs Therapeutics) Business Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. The vast majority of the Company's product sales are generated in the United States with additional sales outside the United States in China and Israel through sublicenses and distribution agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
YMAB has been successfully added to your 